Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma
- 15 March 2004
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (6) , 1007-1013
- https://doi.org/10.1200/jco.2004.05.174
Abstract
Purpose: To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods: p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node–negative, 117 patients; lymph node–positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0% to 10%) or altered (> 10%); p21 was scored as wild-type (>10%) or altered (< 10%); and pRb status was considered wild-type (1% to 50%) or altered (0% or > 50%). Results: As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23%, 32%, 57%, and 93%, respectively (log-rank P < .001), and the 5-year survival rates were 70%, 58%, 33%, and 8%, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion: This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.Keywords
This publication has 22 references indexed in Scilit:
- How Cancer ArisesScientific American, 1996
- The retinoblastoma protein and cell cycle controlCell, 1995
- The Genetic Basis of CancerScientific American, 1995
- p21 is a universal inhibitor of cyclin kinasesNature, 1993
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology DataJournal of the American Statistical Association, 1993
- p53 Mutations in Human CancersScience, 1991
- A genetic model for colorectal tumorigenesisCell, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958